Vaccination of cattle against Mycobacterium bovis

Tuberculosis

Volumn 81, Issue 1-2, 2001, Pages 125-132

  Buddle, B M ^a  

^a AGRESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT;

BCG VACCINATION; CATTLE; CATTLE DISEASE; CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG EFFICACY; IMMUNE RESPONSE; MICROBIAL ATTENUATION; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULIN TEST;

EID: 0034981704     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1054/tube.2000.0254     Document Type: Conference Paper

References (43)

1. The epidemiology of Mycobacterium bovis infection in animals and man: A review
2. Zoonotic tuberculosis due to Mycobacterium bovis in developing countries
3. Tuberculosis in man and animals
4. Vaccination of calves against tuberculosis with BCG
5. The prevention of tuberculosis in cattle. Further investigations to determine the value of the BCG vaccine for the prevention of tuberculosis
6. Bovine tuberculosis and BCG vaccination
7. La tuberculose, avec référence spéciale à la vaccination contre la tuberculose au moyen du BCG
8. Vaccination of cattle with BCG
9. Field experiment with BCG vaccine in Malawi
10. Studies on the vaccination of cattle as a measure against infection with tuberculosis with tire living vole acid-fast bacillus
11. Vaccine protocols to optimise the protective efficacy of BCG
12. The effect of heterologous immunity upon the apparent efficacy of (eg. BCG) vaccines
13. Vaccination of cattle and possums against bovine tuberculosis
14. Immunological responses and protection against Mycobacterium bovis in calves vaccinated with a low dose of BCG
15. Experimental Mycobacterium bovis infection of cattle: Effect of dose of M. bovis and pregnancy on immune responses and distribution of lesions
16. Immune responses induced in cattle by virulent and attenuated Mycobacterium bovis strains: Correlation of delayed- type hypersensitivity with ability to grow in macrophages
17. Protection against mycobacterial disease by means of live vaccines tested in experimental animals
18. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae
19. Auxotrophic vaccines for tuberculosis
20. Vaccination of guinea pigs with nutritionally impaired avirulent mutants of Mycobacterium bovis protects against tuberculosis
21. Induction of a type 1 immune response to a recombinant antigen from Mycobacterium tuberculosis expressed in Mycobacterium vaccae
22. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins
23. Effective, nonsensitizing vaccination with culture filtrate proteins against Mycobacterium bovis infections in mice
24. Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and interleukin-2 against bovine tuberculosis
25. Protection against tuberculosis by a plasmid DNA vaccine
26. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy
27. Differentiation between Mycobacterium bovis BCG-vaccinated and M. bovis-infected cattle by using recombinant mycobacterial antigens
28. Assessment of defined antigens for tire diagnosis of bovine tuberculosis in skin test-reactor cattle
29. In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis
30. New tuberculosis vaccines based on attenuated strains of Mycobacterium tuberculosis complex
31. An esat6 knockout mutant of Mycobacterium bovis produced by homologous recombination will be useful for development of a live tuberculosis vaccine
32. Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis
33. Isolation and characterisation of auxotrophs of Mycobacterium bovis
34. Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis
35. T-cell recognition of Mycobacterium tuberculosis culture filtrate fractions in tuberculosis patients and their household contacts
36. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis
37. Predominant recognition of the ESAT-6 protein in the first phase of infection with Mycobacterium bovis in cattle
38. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis
39. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis
40. CpG DNA: A novel immunomodulator
41. Therapy of tuberculosis in mice by DNA vaccination
42. Effective DNA vaccination of cattle with the mycobacterial antigens MPB83 and MPB70 does not compromise the specificity of the comparative intradermal skin test